320 related articles for article (PubMed ID: 18831725)
1. Luminal B breast tumors are not HER2 positive.
Bhargava R; Dabbs DJ
Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
[No Abstract] [Full Text] [Related]
2. HER2 as a prognostic factor in breast cancer.
Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
[TBL] [Abstract][Full Text] [Related]
3. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
[No Abstract] [Full Text] [Related]
4. Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.
Rao AV; Mohammed WA; Ragoonanan C; Omo-Igbinomwanhia NE
West Indian Med J; 2002 Mar; 51(1):4-9. PubMed ID: 12089875
[TBL] [Abstract][Full Text] [Related]
5. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
Malamou-Mitsi VD; Syrrou M; Georgiou I; Pagoulatos G; Agnantis NJ
J Exp Clin Cancer Res; 1999 Sep; 18(3):357-61. PubMed ID: 10606182
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
7. Correspondence re: Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
Hugh J; Barley R; Dabbagh L
Mod Pathol; 2001 Mar; 14(3):263. PubMed ID: 11266538
[No Abstract] [Full Text] [Related]
8. [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
Brück P; Vilches Cisneros N; Ramos López E; Barboza Quintana O; Ancer Rodríguez J; Flores Gutiérrez JP
Ginecol Obstet Mex; 2006 Oct; 74(10):516-22. PubMed ID: 21961357
[TBL] [Abstract][Full Text] [Related]
9. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
Tubbs RR; Stoler MH
Mod Pathol; 2000 Jan; 13(1):1-3. PubMed ID: 10658903
[No Abstract] [Full Text] [Related]
10. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic targeting in breast cancer].
Penault-Llorca F
Ann Pathol; 2009 Nov; 29 Spec No 1():S71-3. PubMed ID: 19887259
[No Abstract] [Full Text] [Related]
12. Current status of HER2 testing: caught between a rock and a hard place.
Schnitt SJ; Jacobs TW
Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
[No Abstract] [Full Text] [Related]
13. [Prognostic factors of breast cancer].
Tang P; Wei B; Yang WJ; Liu YS; Bu H
Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):73-6. PubMed ID: 21426799
[No Abstract] [Full Text] [Related]
14. HER2/neu amplification in breast cancer: stratification by tumor type and grade.
Hoff ER; Tubbs RR; Myles JL; Procop GW
Am J Clin Pathol; 2002 Jun; 117(6):916-21. PubMed ID: 12047143
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients.
Richter-Ehrenstein C; Müller S; Noske A; Schneider A
Int J Surg Pathol; 2009 Aug; 17(4):323-6. PubMed ID: 19029173
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
Saatee S; Afrakhteh M; Sadrolhefazi B
Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
[No Abstract] [Full Text] [Related]
18. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
[TBL] [Abstract][Full Text] [Related]
19. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
Kurbel S
Med Hypotheses; 2005; 64(6):1182-7. PubMed ID: 15823713
[TBL] [Abstract][Full Text] [Related]
20. [Use of polymerase chain reaction (PCR) as an additional diagnostic method in gynecologic oncology].
Czerwenka KF; Zeillinger R; Kury F; Manavi M; Speiser P; Peschke M; Steinhart U; Hosmann JW; Kubista E
Gynakol Rundsch; 1991; 31 Suppl 2():378-9. PubMed ID: 1686430
[No Abstract] [Full Text] [Related]
[Next] [New Search]
